111 results
Page 2 of 6
8-K
EX-99.1
gz3pul3piuj0v15450
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
EX-99.1
pj6tv6eyexvtuj dy4
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am
8-K
EX-99.1
38334u
24 Oct 23
Regulation FD Disclosure
4:30pm
8-K
ldkvt6rg
15 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-10.2
9f99wrar9fehee4itqww
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
8-K
EX-99.1
oeq78220bn5m ox
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
8-K
EX-4.2
0ghmp n2r
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
8-K
EX-99.2
tidqp 37j
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-10.1
9fd3t
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-99.1
p7lp6t tk7op82a
24 Oct 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
9:41am
8-K
srtdi
6 Apr 22
Bio-Path Holdings Appoints Aline Sherwood to Board of Directors
4:30pm
8-K
EX-99.1
19e3ciim w69c
11 Mar 22
Bio-path Holdings Reports Full Year 2021 Financial Results
7:30am
8-K
ro5 302pkb
25 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-99.1
5tv ints6k
13 Dec 21
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
7:40am